reported that butyrate, a synthetic raw material for short-chain fatty acids, inhibits the glycolytic rate of cancer cells by suppressing the concentrations of GPR109a-AKT signaling-mediated membrane (GLUT1) and cytoplasmic glucose-6-phosphate dehydrogenase (G6PD), thereby exerting anti-cancer effects. The gene discussed is SLC2A1; the disease is cancer.